Razia Deepika, Tokman Sofya, Israr Sharjeel, Mohamed Hesham, Abdelrazek Hesham, Buddhdev Bhuvin, Arjuna Ashwini, McAnally Kendra, Hashimi Samad, Smith Michael A, Bremner Ross M, Walia Rajat, Omar Ashraf
Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA.
Creighton University School of Medicine, Phoenix Regional Campus, Phoenix, AZ, USA.
J Transplant. 2022 Mar 3;2022:3308939. doi: 10.1155/2022/3308939. eCollection 2022.
Persistent orthostatic hypotension (OH) is a lesser-known complication of lung transplantation (LTx). In this retrospective case series, we describe the clinical manifestations, complications, and treatment of persistent OH in 13 LTx recipients.
We identified LTx recipients who underwent transplantation between March 1, 2018, and March 31, 2020, with persistent symptomatic OH and retrospectively queried the records for clinical information.
Thirteen patients were included in the analysis, 9 (69%) had underlying pulmonary fibrosis, and 12 (92%) were male. The median age, height, and body mass index at LTx were 68 years, 70 inches, and 27 kg/m, respectively. Six (46%) patients were deceased at the time of chart abstraction with a median (IQR) posttransplant survival of 12.6 months (6, 21); the 7 remaining living patients were a median of 19.6 months (18, 32) posttransplant. Signs and symptoms of OH developed a median of 60 (7, 75) days after transplant. Patients were treated with pharmacological agents and underwent extensive physical therapy. Most patients required inpatient rehabilitation ( = 10, 77%), and patients commonly developed comorbid conditions including weight loss, renal insufficiency with eGFR <50 ( = 13, 100%), gastroparesis ( = 7, 54%), and tachycardia-bradycardia syndrome ( = 2, 15%). Falls were common ( = 10, 77%). The incidence of OH in LTx recipients at our center during the study period was 5.6% (13/234).
Persistent OH is a lesser-known complication of LTx that impacts posttransplant rehabilitation and may lead to comorbidities and shortened survival. In addition, most LTx recipients with OH at our center were tall, thin men with underlying pulmonary fibrosis, which may offer an opportunity to instate pretransplant OH screening of at-risk patients.
持续性直立性低血压(OH)是肺移植(LTx)一种鲜为人知的并发症。在这个回顾性病例系列中,我们描述了13例肺移植受者持续性OH的临床表现、并发症及治疗情况。
我们确定了2018年3月1日至2020年3月31日期间接受移植且患有持续性症状性OH的肺移植受者,并回顾性查询记录以获取临床信息。
13例患者纳入分析,9例(69%)有潜在肺纤维化,12例(92%)为男性。肺移植时的中位年龄、身高和体重指数分别为68岁、70英寸和27kg/m²。6例(46%)患者在图表提取时已死亡,移植后中位(IQR)生存期为12.6个月(6,21);其余7例存活患者移植后中位时间为19.6个月(18,32)。OH的体征和症状在移植后中位60(7,75)天出现。患者接受了药物治疗并接受了广泛的物理治疗。大多数患者需要住院康复(n = 10,77%),患者常出现合并症,包括体重减轻、估算肾小球滤过率(eGFR)<50的肾功能不全(n = 13,100%)、胃轻瘫(n = 7,54%)和心动过速 - 心动过缓综合征(n = 2,15%)。跌倒很常见(n = 10,77%)。研究期间我们中心肺移植受者中OH的发生率为5.6%(13/234)。
持续性OH是肺移植一种鲜为人知的并发症,影响移植后康复,可能导致合并症和生存期缩短。此外,我们中心大多数患有OH的肺移植受者是身材高大、消瘦且有潜在肺纤维化的男性,这可能为对高危患者进行移植前OH筛查提供机会。